Cancer Treatments and Cardiovascular Toxicity (Position Paper)

Publication Date: 2016

Chairperson: Jose Luis Zamorano & Patrizio Lancellotti

chemotherapy, cardiotoxicity, cardio-oncology, myocardial dysfunction, arrhythmias, ischaemia, early detection, surveillance, cancer therapy

Pocket Guidelines on Cancer Treatment and Cardiovascular Toxicity


2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)


„Advances in treatment have led to improved survival of patients with cancer, but have also increased morbidity and mortality due to treatment side effects. Cardiovascular diseases (CVDs) are one of the most frequent of these side effects, and there is a growing concern that they may lead to premature morbidity and death among cancer survivors. This may be the result of cardiotoxicity, which involves direct effects of the cancer treatment on heart function and structure, or may be due to accelerated development of CVD, especially in the presence of traditional cardiovascular risk factors.”

Skaityti daugiau